Paratek Pharmaceuticals To Present New Data

Paratek Pharmaceuticals said Wednesday it will be presenting data from its omadacycline clinical and microbiology programs at ASM Microbe 2017, to be held June 1-5 in New Orleans. The company said the presentation includes new phase 1 data examining omadacycline in patients with uncomplicated urinary tract infection as well as additional analyses of microbiology data that help further the understanding of how omadacycline may be used in a clinical setting. “We continue to be excited about the potential for this compound to treat severe bacterial infections, particularly when resistance is of concern,” COO Evan Loh said.

Paratek’s lead product candidate, omadacycline, when approved, will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, the company said. Omadacycline is a new, once-daily oral and intravenous broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

By Kristen Tardella